Skip to main content

Table 1 Clinicopathologic characteristics of 472 patients undergoing radical prostatectomy for clinically localized prostate cancer at four medical centers

From: Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer

Variable   Pathological Gleason score ≥ 7 Pathological Gleason score = 6 p value
Number of patients 472 339 133  
age (years, median, range) 65.4 (60.28–69) 65.7 (61.23–69.2) 65.2 (60.03–67.4) 0.123
PSA (ng/ml, median, range) 8.04 (5.78–11.73) 8.98 (6.53–12.06) 7.02 (5.03–9.21) 0.002
fPSA (ng/ml, median, range) 0.91 (0.61–1.35) 0.82 (0.52–1.08) 1.02 (0.87–1.41) 0.800
%fPSA (ratio, median, range) 9.29 (4.76–13.35) 7.23 (4.22–11.8) 11.13 (8.97–14.63) 0.023
p2PSA (pg/ml, median, range) 17 (12–26) 19 (14–29) 14 (10–22) 0.058
%p2PSA (ratio, median, range) 19.60 (15.33–25.79) 20.32 (19.12–26.87) 17.8 (13.91–21.82) 0.007
PHI (median, range) 55.68 (42.24–72.82) 59.53 (51.11–74.61) 45.23 (38.07–59.22) < 0.001
DRE; n (%)
 negative 329 (69.7) 227 (67.0) 102 (76.7)  
 positive 143 (30.3) 112 (33.0) 31 (23.3) < 0.005
Biopsy Gleason score; n (%)
 6 296 (62.7) 179 (52.8) 117 (88.0)  
 7 141 (29.9) 128 (37.8) 13 (9.8)  
  > 7 35 (7.4) 32 (9.4) 3 (2.2) 0.032
Pathological tumor stage; n (%)
 pT2 340 (72.1) 226 (66.7) 114 (85.7)  
 pT3 132 (27.9) 113 (33.3) 19 (14.3) < 0.003
Surgical margin status; n (%)
 R0 339 (71.8) 230 (67.8) 109 (82.0)  
 R1 133 (28.2) 109 (32.2) 24 (18.0) < 0.050
  1. PSA prostate specific antigen - PSA, fPSA free PSA, %fPSA fPSA/PSA, %p2PSA /fPSA ratio, PHI Prostate health index, DRE digital rectal examination, R0 negative surgical margin, R1 positive surgical margin